1.
|
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: ASSO OE-1, EudraCT 2006-006647-31, NCT00525200
|
|
2.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D7913C00046, NCT00536107
|
|
3.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: YUNZHI-BC, NCT00647075
|
|
4.
|
Phase: Phase IV
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ML21343, NCT00774241
|
|
5.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: simcere002, simcere0802, NCT00813332
|
|
6.
|
Phase: Phase IV
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MC#08-002, IIT 12230, NCT00883675
|
|
7.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: MRC-STAMPEDE, EU-205102, MRC-PR08, ISRCTN78818544, EUDRACT-2004-000193-31, NCT00268476
|
|
8.
|
Phase: Phase III, Phase II
Type: Supportive care, Treatment
Status: Active
Age: 17 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: PH-CP010, NCT00518869
|
|
9.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: GEICAM/2006-14, Nº EudraCT 2007-007031-13, NCT00841828
|
|
10.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Any age
Sponsor: NCI
Protocol IDs: MDA-ID-00156, NCI-3410, 3410, NCT00024167
|
|
11.
|
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: SWS-SAKK-16/00, EU-20138, NCT00030771
|
|
12.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: LMU-ADEBAR, EU-20221, NCT00047099
|
|
13.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Under 80
Sponsor: Other
Protocol IDs: FRE-FNCLCC-GETUG-12/0203, EU-20238, NCT00055731
|
|
14.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: DUMC03, DUKE UNIVERSITY MEDICAL CENTER, CLINICAL STUDY PROTOCOL, NCT00090610
|
|
15.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: DOXIL-BCA-3001, NCT00091442
|
|
16.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Over 18
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: DFCI-04006, AVENTIS-DFCI-04006, NCT00095875, PARADIGM TRIAL
|
|
17.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CP02-0452, NCT00095199
|
|
18.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: FRE-FNCLCC-GETUG-15/0403, NCT00104715
|
|
19.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: SWOG-S0421, S0421, NCT00134056
|
|
20.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 30 and over
Sponsor: Other
Protocol IDs: 05-043, NCT00116142
|
|
21.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: IRB 13362B, NCT00117572
|
|
22.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: AVENTIS-FIN-1-2003, FINNISH-URO-OGS-1-2003, PROSTY-FIN-1-2003, NCT00255606
|
|
23.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: 553, NCT00132301
|
|
24.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: D-0410, NCT00153803
|
|
25.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: GBG-GEPARQUATTRO, GBG-40, EU-205101, AVENTIS-GBG-GEPARQUATTRO, ROCHE-AVENTIS-GBG-GEPARQUATTRO, EUDRACT-2005-001546-17, NCT00288002
|
